Segal Lloyd Mitchell 4
4 · Aktis Oncology, Inc. · Filed Jan 12, 2026
Insider Transaction Report
Form 4
Segal Lloyd Mitchell
Director
Transactions
- Conversion
Common Stock
[F1][F2]2026-01-12+19,631→ 19,631 total(indirect: See Footnote) - Conversion
Series A Redeemable Convertible Preferred Stock
[F3][F2]2026-01-12−50,000→ 0 total(indirect: See Footnote)→ Common Stock (13,142 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
[F3][F2]2026-01-12−24,687→ 0 total(indirect: See Footnote)→ Common Stock (6,489 underlying)
Footnotes (3)
- [F1]Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration.
- [F2]Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.
- [F3]The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Signature
/s/ Karen McCarthy, as Attorney-in-Fact|2026-01-12